The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool ...
Results from the international VESALIUS-CV (TIMI 66) clinical trial found that among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes and no history of a prior heart attack or ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with high ...
Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials RAHWAY, N.J.--(BUSINESS WIRE)- ...
Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...
MedPage Today on MSN
Third-generation PCSK9 inhibitor approved for high cholesterol
A third-generation PCSK9 inhibitor, lerodalcibep is indicated as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment ...
AstraZeneca’s small molecule lowered levels of “bad” cholesterol by more than half in patients who had never received treatment for their condition, according to results from an early-stage trial. The ...
Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback